登录新浪财经APP 搜索【信披】查看更多考评等级 基金管理人：招商基金管理有限公司 基金托管人：光大证券股份有限公司 登记机构：招商基金管理有限公司 重要提示 1、招商医药量化选股混合型发起式证券投资基金（以下简称"本基金"）的发售已获中国证监会证监许 可〔2025〕2060号文准予注册。 2、本基金类型为契约型开放式、混合型证券投资基金。 3、本基金的管理人为招商基金管理有限公司（以下简称"招商基金"或"本公司"），托管人为光大证券 股份有限公司，登记机构为招商基金管理有限公司。 4、本基金自2025年12月17日至2025年12月26日（具体办理业务时间见各销售机构的相关业务公告或拨 打客户服务电话咨询）通过销售机构公开发售。基金管理人根据认购的情况可适当调整募集时间，并及 时公告，但最长不超过法定募集期限。 5、募集规模上限 本基金首次募集规模上限为30亿元人民币（不含募集期利息，下同）。 基金募集过程中，募集规模接近、达到或超过30亿元时，基金可提前结束募集。 在募集期内任何一日（含首日），若当日募集截止时间后基金份额累计有效认购申请金额（不包括利 息，下同）合计超过30亿元，基金管理人将采取末日比例 ...

Group 1 - The innovative drug sector has led a strong rebound in the pharmaceutical industry after a prolonged adjustment period, attracting increased market attention and driving the issuance of related thematic funds [1] - Multiple public fund institutions, including浦银安盛基金, 鹏华基金, 招商基金, and 长城基金, have recently filed for medical thematic funds, indicating a growing interest in the sector [1] - As of the report, several medical thematic funds have already entered the issuance phase, including 易方达恒生港股通创新药交易型开放式指数证券投资基金 and 大成恒生医疗保健交易型开放式指数证券投资基金 [1] Group 2 - The pace from fund issuance to establishment has noticeably accelerated, with some funds, such as those from 东方阿尔法基金 and 平安基金, announcing early closure of fundraising [2] - Early closure of fundraising is likely aimed at seizing the current rapid rise in the pharmaceutical sector, allowing funds to enter the market more quickly and potentially achieve better performance [2] - Long城基金's fund manager highlighted that the innovative drug sector has outperformed the pharmaceutical industry this year, driven by a solid fundamental backdrop within the broader "technology bull" market [2] Group 3 - The fundamental reasons for the rise in the innovative drug sector include a prolonged adjustment period from 2021 to 2024, leading to significantly low valuations, particularly in the Hong Kong market [2] - The trend of China's innovative drug industry is upward, with a shift from rapid follow-up to global innovation in drug development, and a notable increase in Chinese companies' overseas licensing since 2020 [2] - Domestic policies are supportive of the innovative drug industry, laying a solid foundation for its long-term development [2] Group 4 - Compared to overseas counterparts, Chinese innovative drug companies have achieved "curve overtaking" in certain areas, with a clear trend of "going global" that is strengthening [3] - There is optimism regarding the explosive growth potential of Chinese innovative drug companies in the future, with positive expectations for their industry and stock price trends [3]